ONC · BeOne Medicines

The thesis

BeOne Medicines' shares are modestly more likely to lead than lag the S&P 500 over the next three months. US sales of its blood-cancer drug BRUKINSA grew 36% in the third quarter, and 2026 revenue guidance rose to $6.9–7.0 billion. The full results of the MANGROVE trial in first-line mantle cell lymphoma, due at the American Society of Hematology (ASH) plenary session on 13 December 2026, test the next label, and the fourth-quarter report with the 2027 outlook settles whether growth lasts.

Third-quarter revenue was $1.89 billion, up 34% from a year earlier, against 30% growth in the second quarter, per the company's 5 November 2026 earnings release (8-K exhibit). Free cash flow was $473.5 million and cash was $5.87 billion on 30 September 2026.

The shares closed at $387.25 on the report day, 5 November 2026, and at $406.96 on 6 November 2026 after five brokers raised targets. They reached a closing high of $424.00 on 10 November 2026 and closed at $415.96 on 12 November 2026. That is below the lowest of the five post-report targets, Wells Fargo's $435.

Bullish and bearish views on BeOne Medicines Ltd.

The bull case on BeOne Medicines Ltd. (ONC), in brief: US BRUKINSA passed $1 billion in a quarter. The bear case: guidance implies a softer fourth quarter.

Bull case

• US BRUKINSA passed $1 billion in a quarter. The third-quarter 10-Q shows US sales of $1,005.1 million, up 36%. Global BRUKINSA sales were $1,390.9 million, up 33.7%.
• Profit is growing faster than sales. GAAP operating income was $418.7 million in the third quarter, up 157%, per the 5 November 2026 release. 2026 GAAP operating income guidance rose to $1.2–1.3 billion from $1.0–1.1 billion.
• Margins widened. Third-quarter GAAP gross margin was 88% against 86% a year earlier, even after a $22 million non-cash POBEVCY impairment. Adjusted gross margin was 90%.
• Brokers raised targets after the report. Benzinga reported on 6 November 2026 targets of $465 from RBC, $463 from Citizens, $448 from Truist, $446 from Barclays and $435 from Wells Fargo.
• First-line lymphoma is the next BRUKINSA label. The FDA granted Priority Review to the MANGROVE filing in previously untreated mantle cell lymphoma, per the company's 5 November 2026 release. MANGROVE cut the risk of progression or death by 43% (hazard ratio 0.57) against bendamustine plus rituximab.
• The pipeline moved toward filings. Tacabrutideg, a BTK protein degrader, met its primary response-rate endpoint in the pivotal Phase 2 part of CaDAnCe-101 in relapsed chronic lymphocytic leukemia (CLL), per the 5 November 2026 release. BeOne plans a potential submission in mid-2027.

Bear case

• Guidance implies a softer fourth quarter. On the 5 November 2026 call, Guggenheim's Michael Schmidt asked why the new range implied flat-to-down fourth-quarter revenue. BeOne's Aaron Rosenberg cited a roughly $50 million third-quarter US BRUKINSA benefit from order timing and an extra shipping day.
• 2027 margin gains look modest. Rosenberg said on 5 November 2026 that 2027 operating expense growth should be at least consistent with recent years and that margin expansion would be "modest". He said Medicare Part D changes will likely turn a modest 2026 tailwind into a flat-to-modest 2027 headwind.
• Insiders sold into the rally. SEC Form 4 filings show Principal Accounting Officer Titus Ball sold 1,559 shares at an average $405.57 on 6 November 2026. General Counsel Henry Lee sold 1,115 shares at an average $400.82 on 5 November 2026 under a Rule 10b5-1 pre-arranged plan. Director Xiaodong Wang sold 31,028 shares at an average $362.97 on 27 October 2026 under a similar plan.
• Amgen-licensed products face pressure. That portfolio sold about $167 million in the third quarter, up 26%, per the 5 November 2026 call. Management flagged XGEVA biosimilars and possible China volume-based purchasing for XGEVA and KYPROLIS.
• US drug-pricing policy is a standing overhang. The 31 August 2026 US agreement ties pricing of future FDA-approved BeOne medicines to other developed markets. An extension to approved products would reach BRUKINSA directly.

Price setup

The shares closed at $415.96 on 12 November 2026, 2.1% below the 52-week intraday high of $424.73 set on 10 November 2026. The closing high is $424.00, also on 10 November 2026. Closes fell on each of the next two sessions, to $419.98 on 11 November 2026 and then $415.96.

The 50-day average was $368.1 and the 200-day average was $327.46 as of 12 November 2026. The shares rose 19.7% over three months from the $347.48 close of 14 August 2026. The 52-week closing low is $260.27 from 11 June 2026.

The post-report gap from $387.25 on 5 November 2026 is the nearest level that would show the report-driven move reversing. Hong Kong and Shanghai trading often sets the US open for this triple-listed name.

Catalysts ahead

• 13 December 2026: Full MANGROVE results at the ASH 2026 Plenary Scientific Session. Tests the size and durability of the first-line mantle cell lymphoma benefit ahead of the FDA Priority Review decision.
• 14 December 2026: BeOne ASH investor event covering MANGROVE and 45 accepted abstracts. Shows whether the hematology pipeline supports growth beyond the current BRUKINSA franchise.
• ~31 December 2026 (est.): Japan submission for first-line mantle cell lymphoma; start of GroundBBreaker-301 and −201 liver-cancer trials. Shows whether the BRUKINSA label expansion and the GPC3 x 4-1BB bispecific program keep the schedule given on 5 November 2026.
• ~26 February 2027 (est.): Fourth-quarter and full-year 2026 report with 2027 outlook. Settles whether 2026 revenue reaches $6.9–7.0 billion, the size of the tax benefit, and whether growth outlasts the Part D and spending headwinds flagged on 5 November 2026.

What would change the view

A weekly close below $326, under the September range low, which would undo the advance since the second-quarter report. Full-year 2026 revenue below the $6.9–7.0 billion guidance range would also break the operating case.

The risks this note tracks, each with what would confirm it:

• Third-quarter growth was flattered by order timing, and underlying US BRUKINSA demand is slowing. Confirmed by: a sequential fourth-quarter revenue decline larger than guidance implies, or US BRUKINSA growth well below the second quarter's 31% at the fourth-quarter report.
• Spending growth and Medicare Part D changes hold back 2027 profit growth. Confirmed by: 2027 guidance showing operating income growth below revenue growth, or a net-pricing headwind larger than management's flat-to-modest description.
• Pirtobrutinib or other BTK-targeting drugs take new-patient share from BRUKINSA in CLL. Confirmed by: published market data or company commentary showing BeOne has lost its new-patient share lead in CLL.
• XGEVA biosimilars and China volume-based purchasing cut Amgen-licensed product revenue after 2026. Confirmed by: inclusion of XGEVA or KYPROLIS in a China purchasing round, or a decline from the portfolio's roughly $167 million quarterly sales.
• Drug-pricing policy erodes the US growth outlook. Confirmed by: US pricing rules that extend the 31 August 2026 international-reference pricing principle to currently approved products.
• Post-report target raises leave little room if the fourth-quarter report disappoints. Confirmed by: brokers cutting targets back below $435, the lowest of the five post-report targets, after the fourth-quarter report or the 2027 outlook.

What it trades with

BeOne trades with large-cap oncology and hematology names, and its moves turn on BRUKINSA's position against other BTK inhibitors in CLL. US drug-pricing headlines hit the group together. The shares are triple-listed on Nasdaq, the Hong Kong exchange and Shanghai's STAR Market, so sentiment toward China-linked healthcare can move them independently of the US biotech index.